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Chronic viral hepatitis is one of the major causes of morbidity and mortality worldwide, affecting more 
than 350 million people1-3 and ranking 
seventh of all causes of death.4 Although 
Australia is considered a low prevalence 
country for hepatitis B and C viruses (HBV and 
HCV), which together affected approximately 
2% of the population in 2016,1 chronic 
viral hepatitis remains a significant cause 
of preventable morbidity and mortality.5 
Liver cancer, predominantly attributable to 
viral hepatitis infection, is Australia’s fastest 
increasing cause of cancer death.6 
Despite the availability of effective testing 
and treatment, significant improvements are 
needed in access to diagnosis and care in 
order to prevent adverse outcomes in those 
affected by HBV,7,8 while the recent availability 
of highly effective new treatments for HCV 
has raised the possibility of elimination 
of infection in Australia.9 High-quality, 
up-to-date information regarding the 
epidemiological characteristics of those most 
affected is crucial for enhancing both public 
health and clinical responses.10 Along with 
survey-based and modelling studies, a key 
source of this information is surveillance for 
notifiable diseases, which records information 
on selected infectious diseases legislated as 
being of public health importance, including 
viral hepatitis, to guide public health 
interventions. These systems, however, rely on 
administrative data sources and compliance 
with public health regulations, and as such 
are often subject to gaps in quality and 
completeness.11,12 
All diagnoses of hepatitis B and hepatitis C 
are required by jurisdictional public health 
legislation to be notified to health authorities 
by the pathology laboratory conducting the 
test (in all jurisdictions) and by the diagnosing 
doctor (in most jurisdictions).13 Notifications 
are classified as newly acquired, where 
there is laboratory or clinical evidence that 
infection was acquired in the past two years, 
or otherwise as unspecified, in accordance 
with national case definitions.14 Those cases 
categorised as unspecified overwhelmingly 
represent chronic cases of HBV and HCV.5 
While compliance with notification 
requirements is high among laboratories, 
historically only a minority of health 
practitioners complied with these regulations 
in relation to unspecified HBV and HCV.15 
Previous research has identified that 
diagnosing doctors appreciate the value 
of public health responses to hepatitis B 
diagnosis; however, time constraints and 
clinical system limitations were barriers.16 
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Abstract
Objective: To assess the impact of an enhanced viral hepatitis surveillance program on data 
completeness and on epidemiological assessment of affected populations. 
Methods: Notified cases of non-acute hepatitis B and C were analysed to determine 
demographic characteristics and risk factors during the period prior to July 2015–June 2016, 
and during enhanced surveillance of the period July 2016–June 2017, during which time 
doctors were contacted for information about new diagnoses. 
Results: During the enhanced period, completeness for country of birth and Indigenous status 
doubled for both hepatitis B and hepatitis C, from 18–37% to 48–65%. The incidence ratio of 
hepatitis C among Aboriginal and Torres Strait Islander people increased from eight-fold to 11.4-
fold, and the proportion of hepatitis B cases reported as born in China and Vietnam relative to 
other countries increased. New data fields identified that 12% of hepatitis C diagnoses occurred 
in a correctional facility, and 2% of hepatitis B cases were healthcare workers. 
Conclusions: Improved data completeness highlighted the underlying epidemiology of 
chronic viral hepatitis, demonstrating the increased burden of infection among specific priority 
populations. 
Implications for public health: Enhanced surveillance provides greater insight into the 
epidemiology of chronic viral hepatitis, identifying groups at risk and opportunities for public 
health action. 
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Although laboratory notifications can 
provide case counts and core demographic 
information such as age, sex and area of 
residence, variables such as Aboriginal and 
Torres Strait Islander status, country of birth, 
occupation and risk factors for infection can 
only be provided by the diagnosing doctor. 
These are particularly important in assessing 
the epidemiological trends relating to chronic 
viral hepatitis, which disproportionately 
affects those born overseas, Aboriginal and 
Torres Strait Islander people and people who 
have injected drugs.5,17 Other information 
obtained from clinical data, such as whether 
the diagnosed person is a healthcare worker 
or resides in a correctional facility, facilitate a 
more thorough public health response.
Victoria implemented a program to enhance 
the collection of these surveillance data in 
July 2016. This was achieved by incorporating 
extra questions into the standard notification 
form, contacting diagnosing doctors by mail 
to emphasise the importance of notifying, 
and facilitating ease of reporting by providing 
simplified pre-filled forms. Prior to the 
commencement of this program, follow-up 
was concentrated upon only those cases 
where the notifying doctor or laboratory 
indicated that the case may be newly 
acquired or where a potential public health 
risk existed (for example, recent surgery, 
or a case being a healthcare worker) and 
complete information was predominately 
limited to those cases. 
The aim of this analysis is to generate an 
overview of the current epidemiology 
of unspecified (chronic) HBV and HCV in 
Victoria, and examine the impact of improved 
reporting on the demography of infection 
and identification of priority populations and 
the incidence of risk factors. It also examines 
changes in the reporting of risk factors before 
and after the implementation of enhanced 
surveillance, assessing the impact of previous 
under-reporting on the ability to accurately 
assess information derived from a surveillance 
system. 
Methods
Data source
We analysed all cases of unspecified HBV 
and HCV infections notified to the Public 
Health Events Surveillance System (PHESS) 
of the Victorian Department of Health and 
Human Services (DHHS) from 1 July 2015 
until 30 June 2017. This includes the one-
year periods before (baseline) and after 
(enhanced) implementation of the enhanced 
surveillance project, which began on 1 July 
2016. Unspecified cases are those with no 
laboratory or clinical evidence to indicate 
infection having been newly acquired, in 
accordance with national case definitions14 
and represent the vast majority of cases.
Variables
Extracted data included age at diagnosis, sex, 
Aboriginal and Torres Strait Islander status, 
country of birth, occupation, area of residence 
(metropolitan or rural/regional), history of 
injecting drug use, whether the case was in 
a correctional facility at the time of diagnosis 
(based on both a specific variable and where 
this was missing, imputed from residential 
address and clinic information) and whether 
the case had ever been a healthcare worker. 
These latter three variables were added to a 
standard data collection form as part of the 
enhanced surveillance program and were not 
able to be assessed for the baseline period. 
Although data were collected for a small 
proportion of cases prior to the pilot (<10%), 
reporting was not systematic and these fields 
were likely to be preferentially recorded for 
cases with these demographic or risk factors 
present, due to the practice of following up 
suspected newly acquired cases.
Analysis
Data completeness was assessed for the 
baseline and enhanced surveillance periods. 
Rates and rate ratios of unspecified HBV and 
HCV notifications were generated for each 
time period according to sex, Aboriginal and 
Torres Strait Islander status, region of birth 
(overseas or Australia) and area of residence 
(metropolitan or non-metropolitan). Due 
to the over-representation of overseas-
born individuals among non-Indigenous 
Australians with HBV, the rate ratio comparing 
Aboriginal and Torres Strait Islander and 
Australian-born non-Indigenous individuals 
was also calculated, and is presented in  
Table 1. 
The proportion of all cases reported as 
Aboriginal and Torres Strait Islander and born 
overseas was assessed, as well as specific 
country of birth for the most common 
countries. Median and interquartile ranges 
were calculated to assess age distribution. 
The proportion of cases reporting a history of 
injecting drug use, occupation as a healthcare 
worker, or being in a correctional facility at 
the time of diagnosis was calculated for the 
enhanced period only.
Population denominator data, according to 
age, sex, area of residence, Aboriginal and 
Torres Strait Islander status and region of 
birth were sourced from the 2016 Australian 
Census,18,19 with adjustments made for the 
period 2015–16 in accordance with the 
change in Estimated Resident Population 
during that time.20
Results
Summary and data completeness
Between 1 July 2015 and 30 June 2017, a 
total of 8,149 cases of unspecified HBV and 
HCV were notified in Victoria. The number of 
notifications decreased during 2016–2017 for 
both HBV (1,917 during baseline and 1,708 
during enhanced) and HCV (2,438 and 2,086), 
see Table 1.
Data completeness for these notifications 
varied substantially according to variable 
and time period. Characteristics such as sex, 
age and postcode of residence, available 
from either laboratory or doctor notification 
information were complete in at least 95% 
of cases, with little difference between the 
baseline and enhanced surveillance periods 
(Table 1). 
Large increases in completeness occurred for 
all remaining variables during the enhanced 
surveillance period. The proportion of cases 
with Aboriginal and Torres Strait Islander 
status missing fell from 63.0% to 34.7% for 
HBV and 77.9% to 45.9% for HCV (Table 1). 
Country of birth reporting also substantially 
improved, with the proportion incomplete 
reducing from 70.9% to 40.7% for HBV 
and 81.9% to 51.2% for HCV. Reporting 
for variables not routinely collected in the 
pre-pilot period was understandably low, 
with fewer than 10% of notifications having 
any information available on injecting drug 
use status, correctional facility status and 
healthcare worker status. In the enhanced 
surveillance period, completeness for these 
variables reached 45–55% (Table 1). 
Demographics and risk factors
During both time periods, the notification 
rate was higher for males than females, 
particularly for HCV (Table 1). The median age 
was higher for HCV (41 and 42 years during 
baseline and enhanced, respectively) than 
for HBV (36 and 37 years). The rate of HCV 
notification was higher in non-metropolitan 
areas of Victoria during both time periods; 
whereas, for HBV it was more than four times 
higher in metropolitan regions (Table 1). 
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The rate of HBV among people identified 
as Aboriginal and/or Torres Strait Islander 
(6.4 per 100,000) was lower than all non-
Indigenous people (13.1) during the first 
time period; however, this may be limited by 
the low number of cases (<5 in Aboriginal 
and Torres Strait Islander people). During the 
enhanced surveillance period, during which 
data completeness reached 65%, rates were 
very similar (18.8 in Aboriginal and Torres 
Strait Islander and 20.0 in all non-Indigenous 
people). However, the rate among Australian-
born non-Indigenous individuals was much 
lower (0.76 per 100,000 during 2015–2016 
and 1.53 per 100,000 during 2016–17), 
leading to rate ratios for Aboriginal and Torres 
Strait Islander compared to other Australian-
born non-Indigenous people of 8.51 and 12.3, 
respectively. The notification rate for HCV was 
higher for Aboriginal and Torres Strait Islander 
people during both time periods, with the 
disparity increasing from eight-fold higher 
during baseline to 11.4-fold higher during 
enhanced, as Aboriginal and Torres Strait 
Islander status completeness increased from 
22% to 55% (Table 1). 
The majority of people diagnosed with 
HBV were born overseas. During both time 
periods the notification rate was more than 
30 times higher in this population and data 
completeness nearly doubled with enhanced 
surveillance, from 29% to 59%. For HCV, rates 
were slightly lower among overseas-born 
residents than Australian-born residents in 
both time periods and data completeness 
improved from 19% to 50% (Table 1). 
The proportion of notification forms 
distributed that were returned by the 
notifying doctor (response proportion) during 
the enhanced surveillance was 59.7%. This 
was lowest in the first month (47.1% in July 
2016); however, remained above 55% for 
the remaining months with the exception of 
January 2017 (50.0%), with no evidence seen 
of declining response proportion over time.
The distribution of cases according to 
country of birth within those born overseas 
also shifted between the two time periods 
(Figures 1 and 2). Although China was the 
most common country of birth for HBV 
cases, the proportion increased during the 
enhanced period (19.6% during baseline 
and 31.5% during enhanced), making up 
nearly one-third of those with a country of 
birth reported during 2016–2017 (Figure 1). 
The proportion born in most other countries 
remained relatively stable; however, there 
was also an increase in the proportion of 
Table 1: Demographic characteristics and risk factors for unspecified hepatitis B and hepatitis C cases, Victoria, 
Australia, 2015-2017, by time period.
Variable
Baseline  
(2015-2016)
Enhanced  
(2016-2017)
Baseline  
(2015-2016)
Enhanced  
(2016-2017)
HBV HCV
Total cases 1,917 1,708 2,438 2,086
 Rate per 100,000 33.1 28.8 42.1 35.1
Age (years)
 Median (IQR) 36 (29–48) 37 (29–50) 41 (33–51) 42 (34–53)
 Range 0–92 0–93 9–93 3–93
Sex
 Male 1,030 (53.7%) 868 (50.8%) 1,575 (64.4%) 1,342 (64.3%)
     Rate per 100,000 36.3 29.8 55.5 46.1
 Female 859 (44.8%) 830 (48.6%) 826 (33.9%) 728 (34.9%)
     Rate per 100,000 29.1 27.5 28.0 24.1
 Not stated 28 (1.5%) 10 (0.6%) 37 (1.5%) 13 (0.6%)a
Aboriginal and Torres Strait Islander status
 Aboriginal and/or Torres Strait Islander 3 (0.2%) 9 (0.5%) 35 (1.4%) 101 (4.8%)
     Rate per 100,000 6.4 18.8 75.0 211.4
 Non-Indigenous 707 (36.9%) 1,107 (64.8%) 505 (20.7%) 1,027 (49.2%)
     Rate per 100,000 13.1 20.0 9.4 18.5
 Australian-born non-Indigenousb 28 (1.5%) 58 (3.4%) 282 (11.6%) 664 (31.8%)
     Rate per 100,000 0.76 1.53 7.60 17.48 
 Not stated 1,207 (63.0%) 592 (34.7%) 1,898 (77.9%) 958 (45.9%)
Area of residence
 Metropolitan 1,766 (92.1%) 1,544 (90.4%) 1,655 (67.9%) 1,343 (64.4%)
     Rate per 100,000 40.3 34.4 37.8 30.0
 Rural and regional 128 (6.7%) 112 (6.6%) 683 (28.0%) 635 (30.4%)
     Rate per 100,000 9.3 7.9 49.4 44.8
 Not stated 23 (1.2%) 52 (3.0%) 100 (4.1%) 108 (5.2%)
Region of birth
 Australia 31 (1.6%) 67 (3.9%) 317 (13.0%) 765 (36.7%)
     Rate per 100,000 0.8 1.7 8.4 19.9
 Overseas 526 (27.4%) 946 (55.4%) 125 (5.1%) 252 (12.1%)
     Rate per 100,000 32.1 56.3 7.3 15.0
 Not stated 1,360 (70.9%) 659 (40.7%) 1,996 (81.9%) 1,069 (51.2%)
History of injecting drug use
 Yes * 24 (1.4%) * 622 (29.8%)
 No * 613 (35.9%) * 260 (12.5%)
 Unknown * 158 (9.3%) * 191 (9.2%)
 Not stated 1,870 (97.5%) 913 (53.5%) 2,302 (94.4%) 1,013 (48.9%)
In Correctional Facility
 Yes * 34 (2.0%) * 244 (11.7%)
 No * 728 (42.6%) * 778 (37.3%)
 Not stated 1,870 (97.5%) 946 (55.4%) 2,274 (93.3%) 1,064 (51.0%)
Health care worker
 Yes * 33 (1.9%) * 35 (1.7%)
 No * 596 (34.9%) * 705 (33.8%)
 Unknown * 147 (8.6%) * 260 (12.5%)
 Not stated 1,897 (99.0%) 932 (54.6%) 2,420 (99.3%) 1,086 (52.1%)
Notes:
Not stated = clinician did not respond to this question; Unknown = clinician responded to this question but stated that status was unknown. 
a: Three additional individuals had sex recorded as ‘other’. 
b: The non-Indigenous Australian-born group was used as the comparator for HBV cases due to the very high representation of overseas-born among the 
non-Indigenous group; see Methods. 
IQR, interquartile range. 
*Data suppressed as completeness was below 10%. 
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Discussion
This study assesses the current epidemiology 
of chronic HBV and HCV in Victoria and the 
impact of enhanced surveillance on the 
accurate measurement of demographic 
and risk factor data for newly diagnosed 
infections. It establishes that chronic HBV 
predominates among those born overseas 
and those living in metropolitan areas, while 
chronic HCV disproportionately affects 
Australian-born residents, those living in 
non-metropolitan regions, Aboriginal and 
Torres Strait Islander people, those with a 
history of injecting drug use and those in 
correctional facilities. Accurate assessment of 
these variables was greatly facilitated during 
the period following the implementation 
of enhanced surveillance, emphasising the 
importance of data completeness in routine 
surveillance systems. 
The improved data collection during the 
enhanced surveillance period showed 
that the disparity between Aboriginal and 
Torres Strait Islander and non-Indigenous 
Victorians in chronic HCV was even greater 
than previously estimated. This suggests 
that the lack of collection of Aboriginal 
and Torres Strait Islander status data was 
disproportionately occurring for Aboriginal 
and Torres Strait Islander people, which may 
also be the case for other datasets in which 
completeness is limited. This has also been 
identified for other conditions in linkage 
studies that combine multiple datasets to 
improve completeness21 and highlights a 
potential concern where those without data 
are categorised as non-Indigenous.5 The data 
also demonstrate that crude comparison of 
rates for Aboriginal and Torres Strait islander 
people with non-Indigenous people, without 
accounting for the very high rates among 
non-Indigenous overseas-born individuals, 
obscures the much greater notification rate 
of HBV among Aboriginal and Torres Strait 
Islander Victorians compared to Australian-
born non-Indigenous people. The disparity in 
HBV prevalence among Aboriginal and Torres 
Strait Islander Australians has been previously 
established in other states22; however, data 
from Victoria are limited, highlighting the 
impact of enhanced surveillance in filling 
gaps in epidemiological information. 
The relatively higher number of cases of 
chronic HCV during the baseline period 
resulted from the subsidy of new highly 
effective antiviral treatment through 
Medicare from March 2016,9 likely leading 
Figure 1: Proportion of unspecified hepatitis B cases in Victoria, Australia with specific risk or demographic factors, 
of those with reporting, by time period 2015-2017.
Notes:
Countries reported represent top 10 most commonly reported countries for hepatitis B. 
*Data suppressed as completeness was below 10%.
IDU = Injecting drug use
cases born in Vietnam and Thailand, and a 
relative decrease in those born in Myanmar, 
the Philippines, India and Afghanistan (Figure 
1). Of those HCV cases born overseas, there 
were increases seen for Vietnam and New 
Zealand, and a decrease for Pakistan (Figure 
2). Both HBV and HCV had a reduction in the 
proportion of cases with country of birth 
categorised as ‘overseas not further defined’ 
(18.1% to 4.0% for HBV and 5.2% to 0.5% for 
HCV). 
During the baseline period, only a small 
minority of cases had IDU status complete 
(2.5% for HBV and 6.5% for HCV). Of those 
with reporting, history of IDU was reported 
for the majority of HCV cases (89.5%) and 
a small proportion of HBV cases (9%). In 
the enhanced period, when completeness 
increased (to 46.4% for HBV and 51.1% for 
HCV), the proportion with a history of IDU 
was 3.8% for HBV and 70.5% for HCV. There 
was also an additional 9.3% of cases for 
HBV and 9.2% for HCV who had IDU status 
reported as unknown (as stated by the 
notifying doctor, Table 1). 
Increased reporting of healthcare worker and 
correctional facility status from a previously 
very low level was also observed for both HBV 
and HCV (Table 1). For HBV, completeness 
of correctional facility status increased 
from 2.5% to 44.6%, while completeness 
of healthcare worker status increased from 
1.0% to 45.4%. Of those with reporting, the 
proportion of cases during the enhanced 
period who were in a correctional facility was 
4.5%, while healthcare workers represented 
5.2% of cases with status reported (Figure 
1). For HCV, correctional facility status 
completeness rose from 6.7% to 49.0%, while 
healthcare worker status completeness rose 
from 0.7% to 47.9%. The proportion identified 
as diagnosed in a correctional facility of those 
with reporting was 23.9%, while healthcare 
workers represented 4.7% of those with 
reporting. During the enhanced period, 
8.5% of HBV cases and 12.5% of HCV cases 
reported ‘unknown’ for healthcare worker 
status (Table 1).
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to an increase in the number of individuals 
being tested for HCV. However, the stability 
of demographic characteristics not related 
to enhanced surveillance – such as age, sex 
and area of residence – suggests that the 
changes in other variables among the cohorts 
of individuals diagnosed between the time 
periods relates to improved completeness, 
rather than any changing epidemiology.
People born overseas constitute 
approximately 30% of the Victorian 
population but more than 90% of those 
diagnosed with HBV, confirming previous 
model-based estimates of burden in this 
community17 and highlighting the need 
for culturally and linguistically appropriate 
information and care. The relative changes 
in country of birth for chronic HBV cases 
may in part relate to the characteristics of 
notifiers. Prior to project implementation, 
a high proportion of notifications were 
received from immigration authority health 
services that have a substantial refugee 
caseload. This may have biased the countries 
of birth recorded in notifications towards 
those countries where a high proportion of 
migration occurred through refugee and 
humanitarian streams, including Myanmar 
and Afghanistan. This could explain previous 
findings of over-representation of these 
refugee communities in surveillance data 
when compared to estimated prevalence23 as 
being driven not only by increased testing, as 
previously hypothesised, but also by higher 
compliance with notification procedures 
among clinicians serving these groups. 
Chronic HCV occurred at a greater rate in 
those currently incarcerated, with residents 
of correctional facilities constituting 10% 
of notifications in the enhanced period, 
despite representing 0.2% of the Victorian 
population.18,24 These data emphasise the 
need for prevention and treatment programs 
for this population. This disparity likely 
relates to the increased prevalence of HCV 
among incarcerated individuals,25 but also 
the high level of screening that occurs for 
prison entrants, which may be much higher 
than the level of diagnosis in the general 
population. This selection bias is an important 
consideration for the use of notifications data, 
which are used as an input for mathematical 
models of models of prevalence, 
diagnosis, and treatment,26,27 given these 
individuals may not be representative of 
the overall population living with HCV. The 
improved information flow from Victorian 
correctional facilities will now allow ongoing 
measurement of variations between these 
populations.
The overall epidemiological patterns 
identified in the priority populations – chronic 
HBV predominating among those born 
overseas and in metropolitan Melbourne, 
and chronic HCV among people who inject 
drugs and people living in non-metropolitan 
Victoria – reflect established modelled 
estimates, suggesting that complete 
notifications data reflect true patterns of 
disease, and could be further used to examine 
trends over time and changes in response 
to public health initiatives. They support the 
validity of modelled estimates in the absence 
of population-level seroprevalence studies 
and also highlight the need for tailored 
healthcare service delivery to the highly 
heterogeneous populations living with 
chronic HBV and with chronic HCV. The ability 
to follow up those cases where there is a 
transmission risk, such as healthcare workers 
conducting exposure prone procedures, 
provides a clear example of the public health 
benefit of improved data collection.
Surveillance data are a vital source 
of information regarding a range of 
communicable diseases, and assessing the 
underlying biases and inherent limitations 
can help explain the findings of analyses of 
these types of data in context and identify 
priorities for improving these systems. 
European research has highlighted the 
limitations of low levels of surveillance data 
completeness,28 with only one-third of cases 
overall having information reporting whether 
the case originated outside the country of 
diagnosis and very low reporting of specific 
country of birth.11 This was also reflected 
in HCV data, where only one-quarter of 
cases had information about transmission 
risks.12 The enhanced surveillance described 
in the current study is implementable 
with a modest investment of resources 
and staff time and could provide a similar 
improvement in data completeness in other 
jurisdictions. The stable response proportion 
during the first year of the project suggests 
this approach is sustainable over time with 
regard to clinicians. Further analysis of the 
Figure 2: Proportion of unspecified hepatitis C cases in Victoria, Australia with specific risk or demographic factors, 
of those with reporting, by study time period, 2015-2017.
Notes:
Countries reported represent top 10 most commonly reported countries for hepatitis C. 
*Data suppressed as completeness was below 10%.
IDU = Injecting drug use
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ongoing response proportion over time, 
and of potential variations in response 
according to health provider type, will help to 
further assess the representativeness of this 
enhanced surveillance data. 
The Victorian DHHS has now embedded the 
enhanced data collection into surveillance 
activities regarding unspecified HBV and HCV. 
Ongoing work to increase data completeness 
will aim to further enhance the accuracy 
and information provided regarding the 
epidemiology of viral hepatitis in Victoria. 
Despite the large gains in information 
achieved, the conclusions drawn may still 
be limited by biases in reporting for those 
variables where completeness remained 
below 50%. The ability of health departments 
to provide notifying clinicians with feedback 
and clinically-relevant information obtained 
through enhanced surveillance systems 
may increase the willingness of clinicians to 
participate and contribute to their ongoing 
improvement. 
As with all surveillance data, these results 
represent only notified cases, which exclude 
those people living with HBV or HCV who 
have not presented to healthcare facilities 
and been offered testing. These limitations 
are of particular importance given that 
the estimated proportion diagnosed in 
Australia is 62% for HBV7 and 75% for HCV.29 
Another key drawback in surveillance data 
is the reliance on clinician knowledge 
– and systematic recording – of patient 
characteristics, which may not always be 
complete. This is demonstrated in this study 
by the significant proportion of cases with 
a healthcare worker or injecting drug use 
variable response of ‘unknown’, indicating 
the clinician did not have the information 
available. This could be improved by clinical 
management systems that promote the 
collection of patient information at the time 
of consultation, rather than through contact 
that occurs after the diagnosis has been 
notified by the laboratory. This enhanced 
surveillance has the potential to improve 
clinicians’ collection of this information 
prospectively, with increasing awareness of 
the importance of surveillance information. 
This analysis represents a comprehensive 
assessment of chronic viral hepatitis 
epidemiology in Victoria. It is the first 
analysis to occur since the implementation 
of enhanced surveillance that allowed 
assessment of variables not previously 
available or sufficiently complete, and 
highlights priority populations for 
enhanced access to care and treatment. It 
also demonstrates the broader impacts of 
improving surveillance data and the potential 
biases inherent in incomplete information. 
Notifications data can be crucial in informing 
the epidemiology of infections in all settings 
and systematic changes, including enhancing 
data completeness, can greatly improve their 
utility in informing public health action. 
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